Robert W. Baird Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $759.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price decreased by research analysts at Robert W. Baird from $940.00 to $759.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price target would suggest a potential upside of 5.11% from the company’s current price.

Several other brokerages have also commented on REGN. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Bernstein Bank dropped their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday. Finally, Sanford C. Bernstein dropped their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Up 0.7 %

REGN stock opened at $722.07 on Wednesday. The company’s 50 day moving average price is $717.27 and its 200 day moving average price is $914.93. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $79.35 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the firm earned $11.86 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post 37.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in REGN. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares in the last quarter. Proficio Capital Partners LLC increased its position in Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after purchasing an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $127,489,000. KBC Group NV increased its position in Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $65,180,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.